Chiusura precedente | 1,6397 |
Aperto | 0,0000 |
Denaro | 0,0000 x N/D |
Lettera | 0,0000 x N/D |
Min-Max giorno | 0,0000 - 0,0000 |
Intervallo di 52 settimane | |
Volume | |
Media Volume | 1.566 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 0,38 |
Rapporto PE (ttm) | 0,02 |
EPS (ttm) | 0,8910 |
Prossima data utili | 26 apr 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
STOCKHOLM, SWEDEN, October 2, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company PharmNovo has successfully completed its clinical phase 1 study with PN6047, a drug candidate developed as a potential treatment for neuropathic pain. The results from the study show that PN6047 is safe and well-tolerated at doses predicted to have clinically relevant effects. Furthermore, PN6047 seems to offer a different safety profile compared to conventional opioids. Ph
STOCKHOLM, SWEDEN, September 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company PharmNovo has reported promising results in a preclinical study of the company’s drug candidate PN6047. The results reaffirm existing safety profile data of PN6047, which is planned to enter clinical phase 2 trials in 2024. PharmNovo is developing a novel treatment for nerve pain, a difficult-to-treat form of pain that often develops into a chronic condition. The company
STOCKHOLM, SWEDEN, September 27, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign successfully has completed a directed share issue to a value of approximately SEK 150 million. The net proceeds will be used to finance a strategic shift to fully focus its operations on the orthobiologic business in the U.S., in light of the extraordinary commercial performance of its high-margin nanosynthetic bone graft OssDsign Catalyst. The new strategy anno